The group company held the 2018 annual board of directors and the board of supervisors to review and approve the annual work report and other related proposals
Release time:
2020-07-22
Group Company Convenes 2018 Board of Directors and Board of Supervisors
to Review and Approve Annual Work Report and Other Related Proposals
News 4 26 , Chairman of the Group Company Jiang Xiaomeng presided over the 10 Meeting of the 10th Board of Directors of the Company, deliberated and approved 22 related reports and proposals such as 2018 annual board of directors report and 2018 annual general manager business report.
General Manager's report pointed out that 2018 is the 31st anniversary of Peak Start-up 60#. According to the five-year development plan and annual business plan, the company has carried out various operation and management work in an orderly manner around the general policy of "determination to reform, deepen management, and promote all-round high-quality development of the enterprise " , the business plan formulated by the board of directors at the beginning of the year was well completed. The company realized operating income of 33.62 .7 billion yuan for the whole year, up 18.95% year on year, net profit attributable to shareholders 58,850.21 yuan, earnings per share reached 1.71 yuan, up 68.87% year on year, reaching a new record high. At the end of the year, total assets 49.01 .7 billion yuan, up 17.38% year on year; net assets attributable to shareholders were 31.63 .1 billion yuan, up 20.38% year on year.
With the deepening of the country's supply-side structural reform, the effect of cement de-capacity has been highlighted, 2018 The supply and demand relationship in most parts of the country has been better improved, and the overall profitability of the industry has been greatly improved. The company's cement subsidiaries adhere to the "cost leadership " strategy, through continuous optimization of organizational structure, strengthen technological transformation, effectively control production costs, improve labor productivity. Daye Jianfeng has continuously strengthened the construction of quality management system, strengthened the advanced nature of process technology, and completed a number of technical improvement projects, such as kiln tail preheater technical transformation, raw material mill technical transformation, kiln tail desulfurization technical transformation, and achieved good results. After scientific arrangement and implementation of the plan, sales volume and price have been improved. Yunnan Jianfeng firmly grasped the key projects and Jinghong market, and won the optimization of key projects with high-quality service and good reputation. While the sales volume increased, it ensured that the price continued to run at a high level. At the end of 2018 , the company made a decision to acquire all the shares of Guizhou huangpinggu longmingchuan cement co., ltd. and will continue to promote the construction of its off-site technological transformation project (with waste heat power generation) of its new dry cement production line with a daily output of 4500 tons of clinker, further expanding the company's main business scale and enhancing its core competitiveness. In
2018 , the growth rate of the pharmaceutical industry slowed down due to policies such as medical insurance fee control, bidding and price reduction, and 4+7 urban drug procurement. However, with the improvement of the aging degree of society and the enhancement of people's awareness of health care, the pharmaceutical market demand is strong. 2018 , Jianfeng Pharmaceutical carried out extensive investigation and project negotiation around the company's strategic planning, and achieved certain results. Jianfeng Pharmaceutical completed the holding and capital increase of Shanghai North Card, and acquired Anhui Zhongwang through Shanghai North Card, laying the foundation for Jianfeng Pharmaceutical to build a bulk drug manufacturing base and further improving the company's pharmaceutical business industry chain; the annual output of 20 .8 billion solid preparation project (international project) in Jinxi production base of Jianfeng pharmaceutical industry has been officially launched, and the planning and design, equipment selection, product screening and other work are progressing in an orderly manner. The establishment of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute will further improve the company's research level of antineoplastic drugs. During the reporting period, the company increased its investment in drug research and development, and the clinical trials of Jianfeng Pharmaceutical's new anti-tumor drug DPT progressed steadily. The preclinical research of Jianfeng Yien antitumor drug JFAN-1001 is progressing smoothly. At present, preclinical toxicological, pharmacodynamic and pharmacokinetic studies have been fully carried out, and patent applications in the United States, Canada, Japan, Europe, Australia and China have been successfully completed. Jianfeng Pharmaceutical also has a number of new drugs in various stages of research and development. It has completed the pharmaceutical research of imatinib mesylate tablets and obtained BE filing. Completed the pharmaceutical research of desvenlafaxine succinate sustained-release tablets and passed the ethical review. New progress has been made in the work of "consistency evaluation " . The process, quality research and bioequivalence test of paroxetine hydrochloride tablets have been completed and reported to the National Drug Examination Center. In addition, in the face of "two-vote system " , "4+7 city drug volume procurement " and other policies brought about by market changes, the company actively formulate differentiated sales policies, integrate regional resources, and make useful attempts for marketing transformation.
2018 , the company's other business sectors also better achieved their business objectives, peak health continued to promote the common development of terminals and e-commerce, through the network platform, exhibitions, media and other ways to carry out investment, according to market changes to improve the marketing model. Jianfeng International Trade has completed the construction of the new warehouse (e-commerce logistics park) project, and introduced Aneng Logistics and Zhongtong Express into the park for operation. Peak Cable actively develop new customers, expand the OEM business, operating income has achieved a greater growth. On the day of
, the company also held the 107 meeting of 6 of the 9th board of supervisors, deliberated and approved the company's 2018 annual board of supervisors work report, 2018 annual financial final accounts report and other 9 related reports and proposals. (Yu Fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31